Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

viatris sante - aprépitant 80 mg - gélule - 80 mg - blanche pour une gélule de 80 mg > aprépitant 80 mg gélule blanche et rose pour une gélule de 125 mg > aprépitant 125 mg - antiémétiques et antinauséeux - classe pharmacothérapeutique - code atc : a04ad12la substance active contenue dans aprepitant viatris est l'aprépitant. aprepitant viatris appartient à un groupe de médicaments appelés « antagonistes des récepteurs de la neurokinine 1 (nk1) ». le cerveau possède une zone spécifique qui contrôle les nausées et vomissements. aprepitant viatris agit en bloquant les signaux vers cette zone, réduisant ainsi les nausées et vomissements. aprepitant viatris gélules est utilisé chez les adultes et les adolescents à partir de 12 ans, en association avec d’autres médicaments pour prévenir les nausées et les vomissements causés par une chimiothérapie (traitement du cancer) qui entraîne des nausées et vomissements importants et modérés (tels que cisplatine, cyclophosphamide, doxorubicine ou épirubicine).

Romania - rumensk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

remedica ltd - cipru - sunitinibum - caps. - 12,5mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza

Romania - rumensk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

remedica ltd - cipru - sunitinibum - caps. - 25mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza

Romania - rumensk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

remedica ltd - cipru - sunitinibum - caps. - 37,5mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza

Romania - rumensk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

remedica ltd - cipru - sunitinibum - caps. - 50mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza

Den europeiske union - estisk - EMA (European Medicines Agency)

viatris limited - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunosupressandid - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Den europeiske union - ungarsk - EMA (European Medicines Agency)

viatris limited - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunszuppresszánsok - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Den europeiske union - rumensk - EMA (European Medicines Agency)

viatris limited - pirfenidonă - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imunosupresoare - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Den europeiske union - rumensk - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - medicamente utilizate în diabet - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 și 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Den europeiske union - litauisk - EMA (European Medicines Agency)

viatris limited - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imunosupresantai - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).